2024
X‐chromosome-wide association study for Alzheimer’s disease
Le Borgne J, Gomez L, Heikkinen S, Amin N, Ahmad S, Choi S, Bis J, Grenier-Boley B, Rodriguez O, Kleineidam L, Young J, Tripathi K, Wang L, Varma A, Campos-Martin R, van der Lee S, Damotte V, de Rojas I, Palmal S, Lipton R, Reiman E, McKee A, De Jager P, Bush W, Small S, Levey A, Saykin A, Foroud T, Albert M, Hyman B, Petersen R, Younkin S, Sano M, Wisniewski T, Vassar R, Schneider J, Henderson V, Roberson E, DeCarli C, LaFerla F, Brewer J, Swerdlow R, Van Eldik L, Hamilton-Nelson K, Paulson H, Naj A, Lopez O, Chui H, Crane P, Grabowski T, Kukull W, Asthana S, Craft S, Strittmatter S, Cruchaga C, Leverenz J, Goate A, Kamboh M, George-Hyslop P, Valladares O, Kuzma A, Cantwell L, Riemenschneider M, Morris J, Slifer S, Dalmasso C, Castillo A, Küçükali F, Peters O, Schneider A, Dichgans M, Rujescu D, Scherbaum N, Deckert J, Riedel-Heller S, Hausner L, Molina-Porcel L, Düzel E, Grimmer T, Wiltfang J, Heilmann-Heimbach S, Moebus S, Tegos T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido M, Pastor P, Sánchez-Valle R, Álvarez V, Boada M, García-González P, Puerta R, Mir P, Real L, Piñol-Ripoll G, García-Alberca J, Royo J, Rodriguez-Rodriguez E, Soininen H, de Mendonça A, Mehrabian S, Traykov L, Hort J, Vyhnalek M, Thomassen J, Pijnenburg Y, Holstege H, van Swieten J, Ramakers I, Verhey F, Scheltens P, Graff C, Papenberg G, Giedraitis V, Boland A, Deleuze J, Nicolas G, Dufouil C, Pasquier F, Hanon O, Debette S, Grünblatt E, Popp J, Ghidoni R, Galimberti D, Arosio B, Mecocci P, Solfrizzi V, Parnetti L, Squassina A, Tremolizzo L, Borroni B, Nacmias B, Spallazzi M, Seripa D, Rainero I, Daniele A, Bossù P, Masullo C, Rossi G, Jessen F, Fernandez V, Kehoe P, Frikke-Schmidt R, Tsolaki M, Sánchez-Juan P, Sleegers K, Ingelsson M, Haines J, Farrer L, Mayeux R, Wang L, Sims R, DeStefano A, Schellenberg G, Seshadri S, Amouyel P, Williams J, van der Flier W, Ramirez A, Pericak-Vance M, Andreassen O, Van Duijn C, Hiltunen M, Ruiz A, Dupuis J, Martin E, Lambert J, Kunkle B, Bellenguez C. X‐chromosome-wide association study for Alzheimer’s disease. Molecular Psychiatry 2024, 1-12. PMID: 39633006, DOI: 10.1038/s41380-024-02838-5.Peer-Reviewed Original ResearchX-chromosome inactivationX chromosomeAssociation studiesAlzheimer's diseaseGenome-wide significant signalsX chromosome-wide association studyGenome-wide association studiesAD casesEscape X chromosome inactivationNon-pseudoautosomal regionRandom X-chromosome inactivationSignificant lociGenetic risk factorsGenetic landscapeLociIndex variantsSignificant signalsAlzheimerRisk factorsXq25FRMPD4Dach2PJA1XWASSignalPATH-35. INTEGRATED GENOMIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS
Kaulen L, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann D, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring J, Brors B, Sahm F, Wick W. PATH-35. INTEGRATED GENOMIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS. Neuro-Oncology 2024, 26: viii186-viii186. PMCID: PMC11553229, DOI: 10.1093/neuonc/noae165.0734.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusRNAseq dataSingle nucleotide variantsCopy number variantsComprehensive genetic analysisRNA sequencing dataCopy number gainCNS lymphomaGermline controlTumor microenvironmentNucleotide variantsSequence dataTranscript groupsTargeting motifGenetic analysisGenetic landscapeJAK/STAT signalingCytotoxic T cell responsesRNA sequencingTolerogenic tumor microenvironmentAberrant somatic hypermutationExpression of CD70T regulatory cellsT cell responsesP20.12.B INTEGRATED GENETIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS
Kaulen L, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann D, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring J, Brors B, Sahm F, Wick W. P20.12.B INTEGRATED GENETIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS. Neuro-Oncology 2024, 26: v118-v118. PMCID: PMC11485591, DOI: 10.1093/neuonc/noae144.399.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusRNAseq dataSingle nucleotide variantsCopy number variantsComprehensive genetic analysisRNA sequencing dataCNS lymphomaCopy number gainTumor microenvironmentGermline controlNucleotide variantsSequence dataTranscript groupsCytotoxic T cell responsesEpstein-Barr virus-positiveTargeting motifGenetic analysisGenetic landscapeJAK/STAT signalingTolerogenic tumor microenvironmentRNA sequencingAberrant somatic hypermutationExpression of CD70T regulatory cellsUtility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.Peer-Reviewed Original ResearchOvarian carcinomaNext generation sequencingPrimary uterine tumorsDiagnostically challenging casesOvarian tumorsPrimary tumorUterine tumorsEndometrial malignancyMetastatic tumorsAdjuvant treatmentClonal relationshipTargeted therapyUtilization of next generation sequencingTumor clonalityGeneration sequencingProtein expression profilesTumorChallenging casesImprove outcomesCarcinomaGold standardGenetic landscapeMalignancyClonalityExpression profilesPreclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCarcinoma, EndometrioidCell Line, TumorCell ProliferationEndometrial NeoplasmsExome SequencingFemaleFocal Adhesion Kinase 1HumansImidazolesMiceNeoplasm GradingOxazepinesProtein Kinase InhibitorsPyrazinesSulfonamidesXenograft Model Antitumor AssaysConceptsFocal adhesion kinaseWhole-exome sequencingEndometrial cancer cell linesVS-4718Cell linesRas/MAPK pathwayPhosphorylated focal adhesion kinaseWestern blot assayWhole-exome sequencing resultsRAF/MEK inhibitionEAC cell linesBlot assayP-FAKGenetic landscapeCell cycleEndometrial cancerGenetic derangementsDefactinibP-MEKGrowth inhibitionRAF/MEKRas/MAPKCell viabilityP-ERKHigh-grade endometrial cancerUnraveling the genetic tapestry of pediatric sarcomeric cardiomyopathies and masquerading phenocopies in Jordan
Azab B, Aburizeg D, Shaaban S, Ji W, Mustafa L, Isbeih N, Al-Akily A, Mohammad H, Jeffries L, Khokha M, Lakhani S, Al-Ammouri I. Unraveling the genetic tapestry of pediatric sarcomeric cardiomyopathies and masquerading phenocopies in Jordan. Scientific Reports 2024, 14: 15141. PMID: 38956129, PMCID: PMC11219879, DOI: 10.1038/s41598-024-64921-9.Peer-Reviewed Original ResearchConceptsExome sequencingSarcomere-related genesMitochondrial-related diseasesAt-risk family membersGenetic architectureGenetic landscapePathogenic variantsGene panelPediatric cardiomyopathyMolecular underpinningsGenetic testingPhenocopiesSarcomeric cardiomyopathiesGenesSequenceStorage disorderFamily membersAt-riskVariantsEarly interventionExomeFamilyGlycogen storage disorderHypertrophic cardiomyopathyCardiomyopathyEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptionsPreclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.Peer-Reviewed Original ResearchFocal adhesion kinaseUC cell linesWhole-exome-sequencingFAK inhibitorCell linesFocal adhesion kinase inhibitionPhosphorylated (p)‑FAKWestern blot assayRAF/MEK inhibitionUterine carcinosarcomaRAS/MAPK pathway genesPreclinical in vitroBlot assayVS-4718Cell cycle assayGenetic landscapePathway genesMAP2KGenetic alterationsDecreased p-ERKCycle assaySuperior tumor growth inhibitionBiologically aggressive tumorsGrowth inhibitionIn vitro activityIntegrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingPatient-derived-xenograftsBase excision repairCopy number lossMultiregion whole-exome sequencingCopy number gainHigh-grade neuroendocrine carcinomaCNV analysisPhylogenetic analysisEvolutionary historyNeuroendocrine cervical cancerHuman papillomavirus DNAMutator phenotypeSensitivity to afatinibGenetic landscapeRecurrent mutationsRNA sequencingGene fusionsMutational landscape analysisExcision repairGenesMutationsPan-HERConsistent with deficiencyNeuroendocrine carcinomaChapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemiaCurrent landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDiseaseComprehensive multi-omic profiling of somatic mutations in malformations of cortical development
Chung C, Yang X, Bae T, Vong K, Mittal S, Donkels C, Westley Phillips H, Li Z, Marsh A, Breuss M, Ball L, Garcia C, George R, Gu J, Xu M, Barrows C, James K, Stanley V, Nidhiry A, Khoury S, Howe G, Riley E, Xu X, Copeland B, Wang Y, Kim S, Kang H, Schulze-Bonhage A, Haas C, Urbach H, Prinz M, Limbrick D, Gurnett C, Smyth M, Sattar S, Nespeca M, Gonda D, Imai K, Takahashi Y, Chen H, Tsai J, Conti V, Guerrini R, Devinsky O, Silva W, Machado H, Mathern G, Abyzov A, Baldassari S, Baulac S, Gleeson J. Comprehensive multi-omic profiling of somatic mutations in malformations of cortical development. Nature Genetics 2023, 55: 209-220. PMID: 36635388, PMCID: PMC9961399, DOI: 10.1038/s41588-022-01276-9.Peer-Reviewed Original ResearchConceptsSingle-nucleus RNA sequencingSpatiotemporal expression patternsSomatic mutationsTarget amplicon sequencingLow allelic fractionsMulti-omics profilingGene setsRNA sequencingFunctional validationCellular organizationExpression patternsGenotype-phenotype correlation analysisGenetic landscapeCortical developmentMutationsGenetic causeUtero electroporationSomatic mosaic mutationsGenesCritical roleMosaic mutationsSequencingNeuronal hyperexcitabilityBrain resectionProfiling
2022
Mutation spectrum of congenital heart disease in a consanguineous Turkish population
Dong W, Kaymakcalan H, Jin SC, Diab NS, Tanıdır C, Yalcin ASY, Ercan‐Sencicek A, Mane S, Gunel M, Lifton RP, Bilguvar K, Brueckner M. Mutation spectrum of congenital heart disease in a consanguineous Turkish population. Molecular Genetics & Genomic Medicine 2022, 10: e1944. PMID: 35481623, PMCID: PMC9184665, DOI: 10.1002/mgg3.1944.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingLaterality defectsUnique genetic architectureCongenital heart diseaseConsanguineous familyGenetic architectureCausal genesCHD genesGenome analysisHomozygous variantGenetic landscapeGenetic lesionsGenomic alterationsHeart diseaseConsanguineous populationFunction variantsRecessive variantsCHD probandsGenesType of CHDMutation spectrumStructural congenital heart diseaseVariantsCHD subjectsAdditional patients
2021
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
Easwar A, Siddon AJ. Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing. Life 2021, 11: 1158. PMID: 34833034, PMCID: PMC8625510, DOI: 10.3390/life11111158.Peer-Reviewed Original ResearchAdditional mutationsChromatin modificationsSignal transductionDNA methylationPhiladelphia chromosome-negative myeloproliferative neoplasmsJAK-STATConstitutive activationGenetic landscapeDriver eventsMyeloproliferative neoplasmsSomatic mutationsMolecular landscapeMutationsMolecular alterationsHematopoietic stem cell neoplasmsSplicingTransductionGenesMethylationLandscapeSequencing panelTranslocationStem cell neoplasmChronic myeloid leukemiaPathwayIntegrated mutational landscape analysis of uterine leiomyosarcomas
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.Peer-Reviewed Original ResearchConceptsHomologous recombination DNA repair deficiencySequencing dataWhole-genome sequencing dataRNA sequencing dataTCGA samplesCopy number variation analysisATRX/DAXXCopy number lossNumber variation analysisDNA repair deficiencyWhole-exome sequencing dataRecurrent somatic mutationsCopy number gainsCancer Genome AtlasPatient-derived xenograftsTumor suppressorAkt geneGenetic landscapeHRD signaturesPTEN geneGenesMost fusionsC-MycMutational signaturesC-myc/
2018
Novel targeted therapies in ovarian and uterine carcinosarcomas.
Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. Novel targeted therapies in ovarian and uterine carcinosarcomas. Discovery Medicine 2018, 25: 309-319. PMID: 30021104.Peer-Reviewed Original ResearchConceptsMultiple genes/pathwaysPI3K/Akt/mTORFemale genital tractEffective treatment strategiesUnmet medical needAkt/mTORGynecologic tumorsPoor prognosisUterine carcinosarcomaAggressive tumorsTreatment modalitiesBiphasic tumorWhole-exome sequencing studiesGenital tractTreatment strategiesCarcinomatous componentCarcinosarcomaMedical needAberrant activationTumorsGenes/pathwaysCell cycle regulationGenetic landscapeSequencing studiesPrognosis
2017
Whole exome sequencing: a state-of-the-art approach for defining (and exploring!) genetic landscapes in pediatric nephrology
Gulati A, Somlo S. Whole exome sequencing: a state-of-the-art approach for defining (and exploring!) genetic landscapes in pediatric nephrology. Pediatric Nephrology 2017, 33: 745-761. PMID: 28660367, DOI: 10.1007/s00467-017-3698-0.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingNew high-throughput sequencing techniquesHigh-throughput sequencing techniquesConventional genomic approachesNovel gene discoveryNext-generation sequencing technologiesNovel genetic findingsHuman reference genomeExome sequencingGenomic approachesGene discoveryReference genomeHuman genomeSequencing technologiesSequencing techniquesGenetic landscapeLinkage analysisGenomeBiological dataGenetic findingsSequencingPhenotypic misclassificationRecent studiesComprehensive genomic testingPowerful toolGenetic landscape of clear cell endometrial cancer and the era of precision medicine
Huang GS, Santin AD. Genetic landscape of clear cell endometrial cancer and the era of precision medicine. Cancer 2017, 123: 3216-3218. PMID: 28485840, PMCID: PMC5907932, DOI: 10.1002/cncr.30743.Commentaries, Editorials and Letters
2016
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinosarcomaClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHistonesHumansMiddle AgedMutationOvarian NeoplasmsPTEN PhosphohydrolaseTelomeraseTumor Suppressor Protein p53Uterine NeoplasmsConceptsEpithelial-mesenchymal transitionWhole-exome sequencingHistone gene clusterMutational landscapeStable transgenic expressionExcess of mutationsMultiregion whole-exome sequencingHistone genesEvolutionary historyPhylogenetic relationshipsGene clusterHistone H2AChromosome segmentsSeparate lineagesCancer genesGenetic landscapeUterine serous carcinoma cell linesTransgenic expressionGenesCarcinoma cell linesGene TP53Frequent amplificationFrequent deletionsChromosome 6pInvasive properties
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply